Ryvu Therapeutics Introduces ONCO Prime Platform for Cancer Research
Ryvu Therapeutics, an innovative clinical-stage drug discovery company, is thrilled to present its new ONCO Prime platform at a major global summit dedicated to RAS therapies. This platform is specifically crafted to identify synthetic lethal targets using advanced patient-derived primary cell cultures. The insights gained from this pioneering approach have uncovered promising new drug targets, particularly in KRAS-mutant colorectal cancer, illuminating its potential applicability across various tumor types.
Noteworthy Presentation at the RAS-Targeted Drug Development Summit
At this year's 6th Annual RAS-Targeted Drug Development Summit, Krzysztof Brzózka, the Chief Scientific Officer, will deliver an in-depth presentation on the ONCO Prime platform. This summit unites top experts and scientists focusing on RAS therapeutic strategies, fostering an environment for significant collaboration.
Diving Deeper into the ONCO Prime Platform
This advanced platform leverages novel cancer models that perfectly balance translational potential with high-throughput capabilities. By using patient-derived cells, ONCO Prime brings together extensive medical histories along with genomic, transcriptomic, and histopathological data, allowing for a correlation between clinical outcomes and molecular insights. Initial findings indicate that the platform may identify overlooked drug targets in KRAS-mutant colorectal cancer, with ongoing screenings adapted for various tumor types.
Insights from Ryvu's Leadership Team
On the platform’s capabilities, Krzysztof Brzózka stated, "We are excited about the rapid progress and the innovative targets identified in KRAS-mutant cells, targets often missed by traditional immortalized cell lines. This achievement showcases the distinct capabilities of our platform, and we anticipate important discussions with the international community around these findings." This statement highlights the potential reevaluation of therapeutic strategies that ONCO Prime could usher in.
Funding and Support for the ONCO Prime Initiative
The ONCO Prime project receives backing from the European Union through the Operational Programme European Funds for Modern Economy for 2021-2027. This initiative aims to forge new fronts in personalized cancer therapies, employing sophisticated techniques based on patient-derived primary cultures and extensive omics characterization. With approximately PLN 26.3 million (around USD 6.6 million) allocated for this project, Ryvu Therapeutics is poised to drive significant advancements in its research endeavors.
The Significance of the RAS-Targeted Drug Development Summit
As an essential gathering for RAS discovery, the 6th Annual RAS-Targeted Drug Development Summit serves a critical role in the progression of cancer therapies. Over 150 influential leaders in RAS-centric research will come together, exchanging insights and strategizing on how to develop effective RAS therapies that enhance outcomes for patients worldwide.
About Ryvu Therapeutics
Established in 2007 and based in Kraków, Ryvu Therapeutics has become a prominent player in drug discovery and development, particularly in small-molecule therapies aimed at emerging oncology challenges. The company is developing a diverse pipeline that employs a range of therapeutic mechanisms and is recognized for its inventive approach to cancer biology.
Ryvu's flagship program, RVU120, is a selective CDK8/CDK19 kinase inhibitor showing promise in treating hematologic malignancies and solid tumors, currently progressing through Phase II clinical trials. The company's commitment to collaboration with leading global organizations, such as BioNTech and Exelixis, exemplifies its dedication to innovation in cancer treatment.
Frequently Asked Questions
What is the ONCO Prime platform?
ONCO Prime is a state-of-the-art drug discovery platform by Ryvu Therapeutics that focuses on identifying unique synthetic lethal targets using patient-derived primary cell cultures.
What potential does ONCO Prime have in treatment?
The platform has discovered novel drug targets, particularly in KRAS-mutant colorectal cancer, and shows promise for application in other tumor types as well.
Who will present at the RAS-Targeted Drug Development Summit?
Krzysztof Brzózka, Chief Scientific Officer of Ryvu Therapeutics, will present detailed insights about the ONCO Prime platform at the event.
How is the ONCO Prime platform funded?
The project receives co-funding from the European Union as part of their Operational Programme European Funds for Modern Economy, along with substantial grant funding.
When did the ONCO Prime platform development start?
Development of the platform began in mid-2023, and significant discoveries have already been made in this short timeframe, showcasing its effectiveness.
